Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
What is Eliphos?
ELIPHOS acts as a phosphate binder. Its chemical name is calcium acetate. Its molecular formula is CHCaO, and its molecular weight is 158.17. Its structural formula is:
Each round, white tablet is printed with "CYP 910". Each tablet contains 667 mg calcium acetate, USP (anhydrous; Ca(CH3COO); MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium, and the following inactive ingredients: polyethylene glycol 8000, NF; sodium lauryl sulfate, NF; and crospovidone, NF.
ELIPHOS Tablets (calcium acetate) are administered orally for the control of hyperphosphatemia in end-stage renal failure.
What does Eliphos look like?
What are the available doses of Eliphos?
Tablet: 667 mg calcium acetate per tablet.
What should I talk to my health care provider before I take Eliphos?
How should I use Eliphos?
ELIPHOS is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD).
The recommended initial dose of ELIPHOS for the adult dialysis patient is 2 tablets with each meal. Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop. Most patients require 3-4 tablets with each meal.
What interacts with Eliphos?
Sorry No Records found
What are the warnings of Eliphos?
Sorry No Records found
What are the precautions of Eliphos?
Sorry No Records found
What are the side effects of Eliphos?
Sorry No records found
What should I look out for while using Eliphos?
Patients with hypercalcemia.
What might happen if I take too much Eliphos?
Administration of ELIPHOS in excess of the appropriate daily dosage may result in hypercalcemia
How should I store and handle Eliphos?
ISTODAX (romidepsin) for injection is supplied as a kit containing 2 vials in a single carton. The carton must be stored at 20° to 25°C, excursions permitted between 15° to 30°C. (See USP Controlled Room Temperature.)Procedures for proper handling and disposal of anticancer drugs should be considered. A guideline on this subject has been published ISTODAX (romidepsin) for injection is supplied as a kit containing 2 vials in a single carton. The carton must be stored at 20° to 25°C, excursions permitted between 15° to 30°C. (See USP Controlled Room Temperature.)Procedures for proper handling and disposal of anticancer drugs should be considered. A guideline on this subject has been published Product: 68151-5204NDC: 68151-5204-0 1 TABLET in a PACKAGE Product: 68151-5204NDC: 68151-5204-0 1 TABLET in a PACKAGE
Chemical StructureNo Image found
Calcium acetate (ELIPHOS), when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration.
Non-Clinical ToxicologyPatients with hypercalcemia.
Therapeutic doses of ticlopidine caused a 30% increase in the plasma half-life of antipyrine and may cause analogous effects on similarly metabolized drugs. Therefore, the dose of drugs metabolized by hepatic microsomal enzymes with low therapeutic ratios or being given to patients with hepatic impairment may require adjustment to maintain optimal therapeutic blood levels when starting or stopping concomitant therapy with ticlopidine. Studies of specific drug interactions yielded the following results:
Patients with end stage renal disease may develop hypercalcemia when treated with calcium, including calcium acetate (ELIPHOS Avoid the use of calcium supplements, including calcium-based nonprescription antacids, concurrently with ELIPHOS.
An overdose of ELIPHOS may lead to progressive hypercalcemia, which may require emergency measures. Therefore, early in the treatment phase during the dosage adjustment period, monitor serum calcium levels twice weekly. Should hypercalcemia develop, reduce the ELIPHOS dosage, or discontinue the treatment, depending on the severity of hypercalcemia.
More severe hypercalcemia (Ca >12 mg/dL) is associated with confusion, delirium, stupor and coma. Severe hypercalcemia can be treated by acute hemodialysis and discontinuing ELIPHOS therapy.
Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia, nausea, and vomiting. Mild hypercalcemia is usually controlled by reducing the ELIPHOS dose or temporarily discontinuing therapy. Decreasing or discontinuing Vitamin D therapy is recommended as well.
Chronic hypercalcemia may lead to vascular calcification and other soft-tissue calcification. Radiographic evaluation of suspected anatomical regions may be helpful in early detection of soft tissue calcification. The long term effect of ELIPHOS on the progression of vascular or soft tissue calcification has not been determined.
Hypercalcemia (>11 mg/dL) was reported in 16% of patients in a 3-month study of solid dose formulation of calcium acetate; all cases resolved upon lowering the dose or discontinuing treatment.
Maintain the serum calcium-phosphorus (Ca × P) product below 55 mg/dL
Hypercalcemia is discussed elsewhere
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
ProfessionalClonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
InteractionsA total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).